ReviewMarine drugs2016
Blue-Print Autophagy: Potential for Cancer Treatment.
Review in Marine drugs, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 34 citations in OpenAlex.
- An organic extract from ascidianFrontiers in chemistry · 2024Article
- Identification of Anhydrodebromoaplysiatoxin as a Dichotomic Autophagy Inhibitor.Marine drugs · 2023Article
- Unraveling the mechanisms of intervertebral disc degeneration: an exploration of the p38 MAPK signaling pathway.Frontiers in cell and developmental biology · 2023Review
- Article
- Systematic profiling of diagnostic and prognostic value of autophagy-related genes for sarcoma patients.BMC cancer · 2021Article
- Blue-Print Autophagy in 2020: A Critical Review.Marine drugs · 2020Review
- The Role of Deubiquitinating Enzymes in the Various Forms of Autophagy.International journal of molecular sciences · 2020Review
- Astrocyte-derived exosomes transfer miR-190b to inhibit oxygen and glucose deprivation-induced autophagy and neuronal apoptosis.Cell cycle (Georgetown, Tex.) · 2020Article
- Microvesicles derived from human Wharton's jelly mesenchymal stem cells enhance autophagy and ameliorate acute lung injury via delivery of miR-100.Stem cell research & therapy · 2020Article
- Marine Drugs Acting as Autophagy Modulators.Marine drugs · 2020Article
- Repurposing Ziyuglycoside II Against Colorectal CancerFrontiers in pharmacology · 2020Article
- Marine Compounds and Autophagy: Beginning of a New Era.Marine drugs · 2018Article
- mTOR independent alteration in ULK1 Ser758 phosphorylation following chronic LRRK2 kinase inhibition.Bioscience reports · 2018Article
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The marine environment represents a very rich source of biologically active compounds with pharmacological applications. This is due to its chemical richness, which is claiming considerable attention from the health science communities. In this review we give a general overview on the marine natural products involved in stimulation and inhibition of autophagy (a type of programmed cell death) linked to pharmacological and pathological conditions. Autophagy represents a complex multistep cellular process, wherein a double membrane vesicle (the autophagosome) captures organelles and proteins and delivers them to the lysosome. This natural and destructive mechanism allows the cells to degrade and recycle its cellular components, such as amino acids, monosaccharides, and lipids. Autophagy is an important mechanism used by cells to clear pathogenic organism and deal with stresses. Therefore, it has also been implicated in several diseases, predominantly in cancer. In fact, pharmacological stimulation or inhibition of autophagy have been proposed as approaches to develop new therapeutic treatments of cancers. In conclusion, this blue-print autophagy (so defined because it is induced and/or inhibited by marine natural products) represents a new strategy for the future of biomedicine and of biotechnology in cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.